[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638668":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":44,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":11,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Ausper Biopharma Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"AHB-171 in Treatment CHB","EXPERIMENTAL",null,[13],"Drug: AHB-171 Injection",{"label":15,"type":10,"description":11,"interventionNames":16},"AHB-171 in Naïve CHB",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","AHB-171 Injection","Subcutaneous injection",[15,9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Bella Lu","CONTACT","0571-86959519","clinicaltrial@ausperbio.com",[30],{"facility":31,"status":11,"city":32,"state":33,"zip":11,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"AusperBio Investigational Site","Jilin City","Jilin","China","CN",{"type":37,"coordinates":38},"Point",[39,40],126.5608,43.84652,{"lat":40,"lon":39},[43],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100638668",false,"NCT07630727","Study of AHB-171 in Chronic Hepatitis B Participants","An Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of AHB-171 Injection in Participants With Chronic Hepatitis B","Inclusion Criteria:\n\n* Able to fully understand and sign the informed consent form (ICF).\n* Male or female participants, aged 18-65 years (inclusive).\n* Body mass index (BMI) meeting the predefined eligibility range.\n* Chronic hepatitis B (CHB) participants with HBsAg or HBV DNA positivity for ≥6 months at screening.\n* At screening, participants meeting predefined ranges of HBsAg, HBV DNA, and ALT according to prior nucleos(t)ide analogue (NA) treatment history (stable prior treatment or treatment-naive), and meeting corresponding prior antiviral treatment duration requirements.\n* Adopt effective contraceptive measures as required\n\nExclusion Criteria:\n\n* History of any severe systemic disease or malignancy other than chronic HBV infection which, in the opinion of the investigator, makes the subject unsuitable for study participation.\n* Prior history of solid organ or hematopoietic stem cell transplantation.\n* History of any other liver disease that the investigator considers unsuitable for trial.History of autoimmune disease or diseases with potential immune activation risk.\n* History or presence of hepatic decompensation at screening.\n* History of primary liver cancer, or diagnosis\u002Fsuspected liver cancer at screening.\n* Imaging or histological evidence of significant liver fibrosis or cirrhosis within 12 months prior to screening, or a liver stiffness measurement indicative of significant fibrosis or cirrhosis at screening. Major trauma or major surgery within 12 weeks prior to screening\n* History of severe allergies (e.g., to ≥2 allergens) or severe allergy to any component of the study drug, or in the opinion of the investigator, makes the subject unsuitable for participation.\n* Severe infection requiring intravenous anti-infective therapy within 2 weeks prior to screening (excluding chronic HBV infection).\n* History of drug abuse, or alcoholism.\n* Blood donation or blood loss exceeding the specified volume within 12 weeks prior to screening, or planned blood donation during the trial period.\n* Use of immunosuppressants, immunomodulators, cytotoxic drugs, or biologics within 6 months prior to screening.\n* Use of any oligonucleotide drugs or interferon therapy within 12 months prior to screening.\n* Vaccination within 4 weeks prior to screening, or planned vaccination during the trial period.\n* Presence of tattoos, active skin diseases, or other conditions that may interfere with subcutaneous drug administration or observation of injection site reactions.\n* Clinically significant abnormal electrocardiogram (ECG) at screening.\n* Tested positive for HIV，HCV or active syphilis infection.\n* Uncontrolled hypertension at screening.\n* Clinically significant abnormal laboratory test as specified in protocol at screening.\n* Currently participating in another clinical trials, or within the washout period.\n* Any other condition or factor which, in the opinion of the investigator, makes the subject unsuitable for trial participation.","ALL","18 Years","65 Years",{"count":56,"type":57},138,"ESTIMATED","INTERVENTIONAL",[60],"PHASE2","The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative\u002Fpositive) and nucleos(t)ide analogue (NA)-treated (HBeAg-negative) participants with chronic hepatitis B (CHB)",[63],"Hepatitis B, Chronic (CHB)","NOT_YET_RECRUITING","2026-06-02",{"date":67,"type":68},"2026-06-05","ACTUAL",{"date":70,"type":57},"2026-07-15",{"date":72,"type":57},"2029-05-31",{"name":5,"class":6},1]